Business Wire

Celltrion Completes Resubmission for Biosimilar Candidate to FDA for Review

Jaa

Celltrion (KRX:068270) has made a resubmission to the FDA (U.S. Food and Drug Administration) to obtain its marketing approval for CT-P10 (rituximab), a proposed mAb biosimilar to Rituxan®.

Additionally, Celltrion plans on making a resubmission for the approval of CT-P6, a proposed biosimilar to Herceptin® in June. In accordance with FDA regulations, the approval procedure will be usually finalized within six months from the resubmission, so Celltrion expects the approval for the U.S. market of the two proposed biosimilars within this year.

Celltrion submitted Biologics License Applications (BLAs) for CT-P10 and CT-P6 to the U.S. FDA in April and May of last year, respectively. However, it received CRLs (complete response letter) from the FDA related to the Warning Letter issued by the FDA in January 2018, regarding the manufacturing facility in Incheon, South Korea.

Celltrion has made progress addressing the concerns raised by the FDA in the Warning Letter and is committed to working with the Agency to fully resolve all outstanding issues with the highest priority and urgency.

FDA has recently notified Celltrion of its re-inspection schedule regarding regular audit results, and separately from this procedure, it has confirmed the resumption of the review procedure for the two proposed biosimilars upon the resubmission of BLAs.

Celltrion official said: “Celltrion is confident that CT-P10 and CT-P6, following the success of REMSIMA® (INFLECTRA®) around the globe, will be the alternative oncology treatment options for the patients in the U.S. with proven record of quality, efficacy and safety to the reference product at an affordable price.”

Celltrion and Teva Pharmaceutical Industries, Ltd. entered into an exclusive partnership to commercialize CT-P10 and CT-P6 in the U.S. and Canada in October 2016. As part of the agreement, Teva is responsible for all commercial activities in the U.S. and Canada, pending regulatory approvals for both products. Celltrion has responsibility for completing all clinical development and regulatory activities.

About CT-P10

CT-P10 was the world’s first monoclonal antibody (mAb) biosimilar approved by the European Commission (EC) for the treatment of oncology. The EC approved CT-P10 for the same indications as the reference product, based on data demonstrating comparability in terms of quality, efficacy and safety. The reference product for CT-P10 is Rituxan®1. Rituxan is used to treat patients with non-Hodgkin’s lymphoma (NHL), chronic lymphocytic leukemia (CLL), rheumatoid arthritis (RA), granulomatosis with polyangiitis (GPA) and microscopic polyangiitis (MPA). Rituximab, the active substance in CT-P10, has been designed to bind specifically to the transmembrane protein CD20 found on both malignant and normal B cells. In 2017, CT-P10 was launched in Europe.

About CT-P6

CT-P6 is an anticancer monoclonal antibody (mAb) biosimilar drug used to treat early breast cancer, metastatic breast cancer, or metastatic gastric cancer whose tumors have either HER2 overexpression or HER2 gene amplification. Similarity of CT-P6 to the reference product, Herceptin®2, was demonstrated in terms of pharmacokinetic, pharmacodynamics, efficacy and safety through multiple global clinical trials. In 2018, CT-P6 was approved by EC and launched in Europe.

About Celltrion, Inc.

Headquartered in Incheon, Korea, Celltrion is a leading biopharmaceutical company, specializing in research, development and manufacture of biosimilar and innovative drugs. Celltrion strives to provide more affordable biosimilar mAbs to patients who previously had limited access to advanced therapeutics. Celltrion received FDA and EC’s approval for INFLECTRA® and Remsima®, respectively, which is the world’s first mAb biosimilar to receive approval from a regulatory agency in a developed country. For more information, visit www.celltrion.com.

1 Rituxan® is a registered trademark of Biogen and Genentech USA, Inc

2 Herceptin® is a registered trademark of Genentech, Inc

Contact information

Celltrion, Inc.
Gunn Lee, +82 32 850 5168
Gunhyuk.lee@celltrion.com
or
Heewon Park, +82 32 850 5356
Heewon.park@celltrion.com

Tietoja julkaisijasta

For more than 50 years, Business Wire has been the global leader in press release distribution and regulatory disclosure.

Tilaa tiedotteet sähköpostiisi

Haluatko tietää asioista ensimmäisten joukossa? Kun tilaat mediatiedotteemme, saat ne sähköpostiisi välittömästi julkaisuhetkellä. Tilauksen voit halutessasi perua milloin tahansa.

Lue lisää julkaisijalta Business Wire

Smithers Viscient announces the appointment of Ian Siragher to the position of Managing Director24.1.2019 13:30Tiedote

Smithers Viscient, a global contract research organization (CRO), today announced the appointment of Ian Siragher to the position of Managing Director. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20190124005031/en/ Ian Siragher, Managing Director, Smithers Viscient Europe (Photo: Business Wire) Siragher will assume operational responsibility for the Smithers Viscient European site in Harrogate, UK. His experience includes high technology start-ups, running SME business, sales, marketing and regulated industry programs within the analytical, pharmaceutical and drug delivery industries. He brings a wealth of entrepreneurial experience with proven strengths in scientific knowledge, operational and strategic planning, coupled with a strong client focus. “We are delighted to welcome Ian to our business,” said Susan Shepherd, President, Smithers Viscient. “Ian is an excellent appointment for us; he is a proven operational leader

HCL Technologies Honors Humanitarian Leaders at the 2019 World Economic Forum in Davos24.1.2019 13:22Tiedote

HCL Technologies, a global technology company, today announced its Goodwill Champions Awards Night to honor humanitarian leaders from around the world. The event will take place on January 24th, 2019, at the HCL Pavilion in Davos and will celebrate these heroic organizations committed to pursuing distinct noble causes, primarily focused on global education, youth development, and women empowerment. This is the first year the awards have been presented, and HCL Technologies plans to issue them each year in a global forum. The award recipients are Katja Iversen, CEO of Women Deliver, which advocates for global investments in gender equality and health; Olajumoke Adekege, Founder of Young Business Agency, which provides employability skills training and recruitment services to young job seekers globally; Chiara Tiles, Founder of We Do it Together – which produces films, documentaries, TV, and other forms of media, uniquely dedicated to the empowerment of women; Baillie Aaron, Founder and

P&G Joins TerraCycle’s Loop – an Environmentally Friendly and Convenient E-Shopping Platform – With 11 Household Brands24.1.2019 13:00Tiedote

The Procter & Gamble Company (NYSE:PG) today announced the introduction of reusable, refillable packaging on some of its most popular products as part of a new effort that aims to change the world’s reliance on single use packaging and disposable waste. Additionally, new “collect and recycle” circular solutions that help eliminate waste were also introduced as part of a partnership with LoopTM, a circular e-commerce platform developed by international recycling leader TerraCycle. Many of P&G’s largest global brands, including PanteneTM, TideTM, CascadeTM and Oral-BTM will participate in this innovative platform later this year. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20190124005087/en/ Pantene is introducing a unique bottle made with lightweight, durable aluminum for its shampoo and conditioner. (Photo: Business Wire) Loop is a first of its kind global packaging and shopping circular solution which aims to improve the e

RSM and DSI Agree to Cross-Border Insolvency Strategic Alliance24.1.2019 13:00Tiedote

Two well-known and respected firms in the global restructuring industry have formed a strategic alliance and international collaboration to further support their respective clients amid a growing wave of cross-border insolvency and international restructuring projects. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20190123005735/en/ U.K.-based restructuring practice RSM Restructuring Advisory LLP ("RSM"), part of audit, tax and consulting firm RSM UK, and U.S.-based restructuring firm Development Specialists, Inc. (DSI), have announced an agreement to collaborate and augment each respective firm's services in dealing with transnational cases. "We're delighted to announce that we'll be collaborating with DSI on cross-border projects,” said Graham Bushby, a Partner and Head of Restructuring Advisory at RSM. “DSI is working on some significant transnational cases and brings a wealth of experience to the arena, which RSM can capa

Total Eren and NBT Secure the Financing for the First Phase of The 250 MW Syvash Wind Project in Ukraine from a Consortium Led by EBRD24.1.2019 11:00Tiedote

NBT AS (“NBT”), a utility-scale wind power developer based in Oslo, and Total Eren SA (“Total Eren”), a leading renewable energy Independent Power Producer (“IPP”) based in Paris, have signed definitive financing agreements for the first phase of a 250 MW wind project located in the Kherson region of Ukraine. The €155M financing agreement was signed at a special meeting of Ukraine’s National Investment Council in Davos. The project’s start of construction is imminent. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20190124005105/en/ The onshore wind project, called Syvash wind farm (“Syvash”) has been developed by Norway-based NBT together with France-based Total Eren. At its full capacity, Syvash represents a €380 million total investment. Syvash will consist of 64 wind turbines and will be located on 1,300 hectares of land in the southern Kherson region of Ukraine. Once completed, it is expected to become the country’s large

STARMUS V, Host of The Stephen Hawking Medal, Hosts a Special Evening in Davos at WEF with Jean-Michel Jarre, Brian May and Luminary Scientific Panel24.1.2019 11:00Tiedote

This year, WEF was treated to a rare panel discussion bridging the fields of astronomy and music. Global CEOs and international media had the opportunity to hear from Dr. Brian May, Jean-Michel Jarre and Dr. Garik Israelian discuss STARMUS and the special connection between science and music. Flanked by a panel of renowned scientists, astronauts, and Nobel laureates, Jean-Michel Jarre introduced his groundbreaking tribute to the Apollo Missions for their 50th Anniversary. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20190124005171/en/ WEF panel for STARMUS, Michel Mayor, Jean-Michel Jarre, Garik Israelian, and moderator Marco Larsen engage with the Davos audience. Photo by: Andres Eggenberger The esteemed panel included Swiss Astronaut Claude Nicollier, Garik Israelian, Brian May, and Michel Mayor. (Special thanks to the support from Kaspersky Labs and to the Stephen Hawking Medal for Science Communication sponsor, Omega.) T

Uutishuoneessa voit lukea tiedotteitamme ja muuta julkaisemaamme materiaalia. Löydät sieltä niin yhteyshenkilöidemme tiedot kuin vapaasti julkaistavissa olevia kuvia ja videoita. Uutishuoneessa voit nähdä myös sosiaalisen median sisältöjä. Kaikki STT Infossa julkaistu materiaali on vapaasti median käytettävissä.

Tutustu uutishuoneeseemme